Tetraphase
Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage
biopharmaceutical company developing novel antibiotics for serious and
life-threatening multidrug-resistant (MDR) bacterial infections, today
announced that it has been selected for addition to the NASDAQ
Biotechnology Index® (Nasdaq:^NBI). The annual re-ranking of the NASDAQ
Biotechnology Index will become effective upon market open on Monday,
December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are
classified as either biotechnology or pharmaceutical according to the
Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index
is calculated under a modified capitalization-weighted methodology and
ranked on annual basis. All securities in the NASDAQ Biotechnology Index
are listed on the NASDAQ Global Market or the NASDAQ Global Select
Market, and meet minimum market value and share volume requirements
among other criteria.
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology Index(SM) Fund. In addition, options based on the iShares
NASDAQ Biotechnology Index Fund trade on various exchanges. For more
information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its
proprietary chemistry technology to create novel antibiotics for serious
and life-threatening multidrug-resistant (MDR) bacterial infections,
including many of the MDR Gram-negative bacteria highlighted as urgent
public health threats by the Centers for Disease Control and Prevention
(CDC). Tetraphase's lead product candidate, eravacycline, is a fully
synthetic tetracycline derivative being developed as a broad-spectrum
intravenous and oral antibiotic in the IGNITE program (Investigating
Gram-negative Infections Treated with Eravacycline). Under this program,
two Phase 3 clinical trials are ongoing: IGNITE 1 for the indication of
complicated intra-abdominal infections (cIAI) and IGNITE 2 for
complicated urinary tract infections (cUTI). Tetraphase has created more
than 3,000 novel tetracycline analogs using its technology platform; in
addition to eravacycline, Tetraphase has generated multiple preclinical
antibiotic candidates that are currently being evaluated for clinical
suitability. Please visit www.tphase.com
for more company information.
Forward-Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, and other statements
containing the words "anticipates," "believes," "expects," "plans,"
"will" and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: whether our cash resources will be sufficient to fund our
continuing operations for the period anticipated; whether results
obtained in preclinical studies and early clinical trials will be
indicative of results obtained in future clinical trials; whether
eravacycline will advance through the clinical trial process on a timely
basis and receive approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether, if
eravacycline obtains approval, it will be successfully distributed and
marketed; and other factors discussed in the "Risk Factors" section of
our most recent quarterly report on Form 10-Q, filed with the Securities
and Exchange Commission on November 10, 2014. In addition, the
forward-looking statements included in this press release represent our
views as of December 15, 2014. We anticipate that subsequent events and
developments will cause our views to change. However, while we may elect
to update these forward-looking statements at some point in the future,
we specifically disclaim any obligation to do so.
Copyright Business Wire 2014